Neurobiology and Physiology of the Endocannabinoid System

<p>Preface</p> <p>I. Setting the scene and introductory chapters</p> <p>1. Distribution of the endocannabinoid system: linking signalling and development<br>Michaela Dvorakova and Anna Kalinovsky</p> <p>2. The endocannabinoid system, immunomodulation, and LPS-induced inflammation<br>Elliot Lloyd, Nina Nguyen and Judith Hellman</p> <p>3. Physiology of the endocannabinoid systems: imaging and the use of positron emission tomography (PET)<br>Claudia Poluga, Cassis Varlow, Neil Vasdev, Isabelle Boileau and Laura M. Best</p> <p>4. The endocannabinoid system and aging<br>Prof. Vahid Reza Askari</p> <p>5. The endocannabinoid system and post traumatic stress disorder (PTSD): a new narrative<br>Luke Ney, Kevin M. Crombie and Leah M. Mayo</p> <p>II. Neurobiology of the endocannabinoid system</p> <p>6. The protective effect of the endocannabinoid system in neurotoxin induced damage to hippocampal neurons: a focus on light and electron microscopy <br>Rita Yakovlevna Gordon, Valentina Kitchigina and Irina Mikheeva</p> <p>7. Endocannabinoid Signaling and excitatory and inhibitory synapses<br>Jian Liang and Corette J. Wierenga</p> <p>8. The endocannabinoids and potassium channels: an updated narrative <br>Yu-Fung Lin</p> <p>9. Social interactions and neural activity: linking cellular studies and endocannabinoid signalling <br>Cheryl McCormick</p> <p>10. Exercise and Parkinson's disease: linking in the cannabinoid type 1 (CB1) and type 2 (CB2), and mu-opioid receptors<br>Marucia Chacur Sr., Caroline Cristiano Real Gregório and Karina Henrique Binda</p> <p>11. Endocannabinoids and inhalant misuse: neuropsychological aspects<br>John Woodward</p> <p>12. Fatty acid amide hydrolase (FAAH) in substance use disorders: FAAH regulation and inhibition in cannabis, alcohol, nicotine, stimulant, and opioid use disorders<br>Garth E. Terry and Greta Niemela</p> <p>13. Treatment of pain with dual fatty acid amide hydrolase (FAAH) enzyme and human soluble epoxide hydrolase (sEH) enzyme inhibitors: interlinking the endocannabinoid system<br>Stevan Pecic and Ram Kandasamy</p> <p>14. WWL70: linking the hydrolyses 2-arachidonoylglycerol, endocannabinoid and eicosanoid pathways: therapeutic potential and neurological disease<br>Mikiei Tanaka and Yumin Zhang</p> <p>15. Endocannabinoid catabolic enzyme inhibitors and pain alleviation <br>Sidney Stevens Negus and Clare Diester</p> <p>16. The endocannabinoid system in health and disease: features in epilepsy<br>Christopher Martínez-Aguirre, Maria de los Angeles Nuñez-Lumbreras and Luisa Lilia Rocha</p> <p>17. The endocannabinoid system and autoimmune demyelination: a focus on multiple sclerosis<br>Ana Bernal-Chico, Andres Baraibar, Alvaro Moreno-Garcia, Teresa Colomer, Ester Sanchez, Carmen Utrilla, Carlos Matute and Susana Mato</p> <p>18. Endocannabinoid signaling and the lateral habenula<br>Jiang-Hong Ye</p> <p>19. On the interplay among endocannabinoid, noradrenergic and glucocorticoid systems: evidence from aversive memory studies<br>Moisés Dos Santos Corrêa, Raquel Fornari, Cristina A. Stern, Leandro José Bertoglio and Lucas Gazarini</p> <p>III. Receptor biology and responses </p> <p>20. Adenosine A2A-cannabinoid CB1 receptor heteromers in the brain: From trans-inhibition to trans-activation <br>Ester Aso and Francisco Ciruela</p> <p>21. Hippocampal CB1, CB2 receptors, the endocannabinoid system and fear memory <br>Ana Maria Raymundi and Cristina A. Stern</p> <p>22. Beta-caryophyllene, the CB2 cannabinoid receptor-specific agonists and wound healing <br>Prof. S. Koyama and Thomas Heinbockel</p> <p>23. The nigrostriatal dopaminergic pathway: impact of WIN 55212-2 as a potent cannaboinoid receptor agonist <br>Enzo Perez-Valenzuela and Jose Antonio Fuentealba Evans</p> <p>24. Peripheral cannabinoid receptor 1 antagonists and impact on adipocytes <br>Morvarid Kabir</p> <p>25. Endocannabinoid system receptors in plasma membranes : extraction, lipid rafts and the cortex <br>Changiz Taghibiglou and Hajar Miranzadeh Mahabadi</p> <p>26. Applications to wound healing: cannabinoid receptor 1 antagonism and collagen deposition<br>Inês Correia-Sa</p> <p>27. Role of the Transient Receptor Potential Vanilloid 1 (TRPV1), a component of the endocannabinoid system, in anxiety, depression, and cocaine addiction<br>Carmen S. Maldonado-Vlaar and Wickensonn Norze</p> <p>28. Allosteric modulators of the endocannabinoid system: Org27569 and cannabinoid receptor 1 (CB1)<br>Dai Lu</p> <p>29. Naturally occurring DELTA-9-tetrahydrocannabinol-derivatives and binding to CB1 and CB2 receptors: Linking in the endocannabinoid system<br>Irene Reyes-Resina, Rafael Rivas-Santisteban, Iu Raïch, Claudia Llinás del Torrent, Jaume Lillo, Rafael Franco and Gemma Navarro</p> <p>IV. Profiles and behaviour of selective endocannabinoids</p> <p>30. New cannabinoid receptor type 1 and 2 agonists and applications to understanding the endocannabinoid system<br>Manuel Faundez-Parraguez</p> <p>31. Fatty acid amide hydrolase, the endocannabinoid anandamide and neurological disease <br>Filomena Fezza</p> <p>32. The endocannabinoid-system in the immuno-biology of dendritic cells <br>Dipyaman Ganguly</p> <p>33. Palmitoylethanolamide and other anandamide congeners in neuroinflammation-based disorders: linking in the endocannabinoid system <br>Enza Palazzo</p> <p>34. Endocannabinoid modulation of synaptic function and behavior in the dorsomedial hypothalamus<br>Karen M. Crosby</p> <p>35. Key role of anandamide and the endocannabinoid system in the modulation of cardio-renal homeostasis<br>Prof. Virna M. Martín Gimenez and Walter Manucha</p> <p>36. The endocannabinoid system: Signaling and social motivation<br>Roberta Monterazzo Cysneiros and Fernanda Ribeiro</p> <p>V. Exogenous, synthetic other compounds linking in the endocannabinoid system</p> <p>37. Safety and toxicology of the dietary cannabinoid beta-caryophyllene<br>Prof. George Oliveira Sr., Bruna Silva, Ana Santos C. L. da Silva and Luciano Silva Lopes</p> <p>38. Synthetic cannabimimetics: an overview <br>Prof. M. Kassiou</p> <p>VI. Compartive studies in non neurological systems </p> <p>39. Non Neurological Aspects of the　 Endocannabinoid System: Non Alcoholic Fatty Liver Disease<br>Dr. R. Ghazali</p> <p>40. Components of the Endocannabinoid system: Hepatic expression levels of the cannabinoid receptors and microRNAs<br>Sema Bolkent and Zeynep Mine Coskun</p> <p>41. Tumour growth and the endocannabinoid system: investigating CB2 agonists<br>Josee Guindon, Isabel Castro-Piedras, Melissa McHann and Robert Barnes</p> <p>42. Linking Endocannabinoid System, Palmitoylethanolamide and Sarcopenia in view of therapeutic outcomes<br>Susanna Molinari, Eleonora Maretti, Renata Battini and Eliana Leo</p> <p>VII. Resources</p> <p>43. Endocannabinoids and Resources <br>Rajkumar Rajendram</p>